TLX is a $1.5bn biotech which has been under significant pressure since it reported for the December quarter primarily because cash reserves had more than halved to just over $22m. The news that it had received regulatory approval for its lead prostate cancer imaging product illuccix is clearly now regarded as old news and its all about commercialisation – the co-founders selling over 8% of their holding in the business hasn’t helped market confidence.
scroll
Thursday 28th March – ASX200 +80pts, All Time High, Retail Sales
Close
Performance for February & 4 stocks we like here and now
Close
Thursday 28th March – DOW up +477pts, SPI up +60pts
Close
MM is neutral TLX
Add To Hit List
Related Q&A
Relevant suggested news and content from the site
Podcast
LISTEN
Thursday 28th March – ASX200 +80pts, All Time High, Retail Sales
Daily Podcast Direct from the Desk
Video
WATCH
Performance for February & 4 stocks we like here and now
Recorder Friday 8th March
Podcast
LISTEN
Thursday 28th March – DOW up +477pts, SPI up +60pts
Daily Podcast Direct from the Desk
Members only
UNLOCK MARKET MATTERS NOW
Take a free trial.
No payment details required.